ImmuPharma plc (LON:IMM – Get Free Report) was down 9.4% on Thursday . The company traded as low as GBX 3.82 ($0.05) and last traded at GBX 3.90 ($0.05). Approximately 12,650,292 shares changed hands during mid-day trading, a decline of 36% from the average daily volume of 19,725,383 shares. The stock had previously closed at GBX 4.31 ($0.05).
ImmuPharma Price Performance
The company has a fifty day moving average of GBX 2.67 and a 200-day moving average of GBX 2.01. The firm has a market capitalization of £15.92 million, a PE ratio of -382.20 and a beta of 1.53.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Further Reading
- Five stocks we like better than ImmuPharma
- Overbought Stocks Explained: Should You Trade Them?
- Archer Aviation Lands BlackRock Investment—What’s Next for ACHR?
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Buffett Buys More Occidental Petroleum—Sticking to His Playbook
- Profitably Trade Stocks at 52-Week Highs
- CVS Health: Earnings Beat Ignites Stock Rally
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
